EFPIA objects to ‘pressure’ from EMA over theoretical medicines shortages
This article was originally published in Scrip
EFPIA, the federation of R&D-based industry associations, is using concern about the impact of forthcoming legislation on drug shortages to call for the European Medicines Agency to look more closely the impact of low prices. EFPIA is warning the agency that it must find a pragmatic way to implement the highly problematic Falsified Medicines Directive.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.